Highlights in melanoma from ASCO 2024

Immunotherapy significantly increases the number of patients free from bowel cancer

ASCO 2024: Lung cancer roundup

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

ASCO 2024: Advances in NSCLC

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Manageable safety profile with early efficacy of Tec-DR in NDMM

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer